Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13180
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlpen, K.-
dc.contributor.authorMaclnnis, R. J.-
dc.contributor.authorVajdic, C. M.-
dc.contributor.authorLai, J.-
dc.contributor.authorDowty, J. G.-
dc.contributor.authorKoh, E. S.-
dc.contributor.authorHovey, E.-
dc.contributor.authorHarrup, R.-
dc.contributor.authorNguyen, T. L.-
dc.contributor.authorLi, S.-
dc.contributor.authorJoseph, D.-
dc.contributor.authorBenke, G.-
dc.contributor.authorDugu�, P. A.-
dc.contributor.authorSouthey, M. C.-
dc.contributor.authorGiles, G. G.-
dc.contributor.authorNowak, A. K.-
dc.contributor.authorDrummond, K. J.-
dc.contributor.authorSchmidt, D. F.-
dc.contributor.authorHopper, J. L.-
dc.contributor.authorKapuscinski, M. K.-
dc.contributor.authorMakalic, E.-
dc.date.accessioned2024-12-11T00:34:35Z-
dc.date.available2024-12-11T00:34:35Z-
dc.date.issued2024-
dc.identifier.issn27679764 (ISSN)-
dc.identifier.urihttps://swslhd.intersearch.com.au/swslhdjspui/handle/1/13180-
dc.description.abstractGlioma is a rare and debilitating brain cancer with one of the lowest cancer survival rates. Genome-wide association studies have identified 34 genetic susceptibility regions. We sought to discover novel susceptibility regions using approaches that test groups of contiguous genetic markers simultaneously. We analyzed data from three independent glioma studies of European ancestry, GliomaScan (1,316 cases/ 1,293 controls), Australian Genomics and Clinical Outcomes of Glioma Consortium (560 cases/2,237 controls), and Glioma International Case-Control Study (4,000 cases/2,411 controls), using the machine learning algorithm DEPendency of association on the number of Top Hits and a region-based regression method based on the generalized Berk?Jones (GBJ) statistic, to assess the association of glioma with genomic regions by glioma type and sex. Summary statistics from the UCSF/Mayo Clinic study were used for independent validation. We conducted a meta-analysis using GliomaScan, Australian Genomics and Clinical Outcomes of Glioma Consortium, Glioma International Case-Control Study, and UCSF/Mayo. We identified 11 novel candidate genomic regions for glioma risk common to multiple studies. Two of the 11 regions, 16p13.3 containing RBFOX1 and 1p36.21 containing PRDM2, were significantly associated with female and male glioma risk respectively, based on the results of the meta-analysis. Both regions have been previously linked to glioma tumor progression. Three of the 11 regions contain neurotransmitter receptor genes (7q31.33 GRM8, 5q35.2 DRD1, and 15q13.3 CHRNA7). Our region-based approach identified 11 genomic regions that suggest an association with glioma risk of which two regions, 16p13.3 and 1p36.21, warrant further investigation as genetic susceptibility regions for female and male risk, respectively. Our analyses suggest that genetic susceptibility to glioma may differ by sex and highlight the possibility that synapse-related genes play a role in glioma susceptibility. �2024 The Authors.-
dc.publisherAmerican Association for Cancer Research Inc.-
dc.subjectBrain Neoplasms Female Genetic Predisposition to Disease Genome-Wide Association Study Glioma Humans Male Polymorphism, Single Nucleotide brain tumor genetic predisposition genetics human single nucleotide polymorphism-
dc.titleRegion-Based Analyses of Existing Genome-Wide Association Studies Identifies Novel Potential Genetic Susceptibility Regions for Glioma-
dc.typeJournal Article-
dc.description.affiliatesCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia The Kirby Institute, UNSW Sydney, Sydney, Australia Australian Genome Research Facility, St Lucia, Australia South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Liverpool, Australia Liverpool and Macarthur Cancer Therapy Centres, Liverpool Hospital, Liverpool, Australia Ingham Institute for Applied Medical Research, Liverpool, Australia Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, Australia Faculty of Medicine, Prince of Wales Clinical School UNSW Sydney, Sydney, Australia Royal Hobart Hospital, Hobart, Australia University of Tasmania, Hobart, Australia Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom Murdoch Children?s Research Institute, Royal Children?s Hospital, Parkville, Australia De-partment of Medicine and Surgery, The University of Western Australia, Perth, Australia School of Public Health and Preventative Medicine, Monash University, Clayton, Australia Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia Medical School, University of Western Australia, Crawley, Australia Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Australia Department of Surgery, University of Melbourne, Parkville, Australia Faculty of Information Technology, Monash University, Clayton, Australia-
dc.identifier.doi10.1158/2767-9764.CRC-24-0385-
dc.type.studyortrialArticle-
dc.identifier.journaltitleCancer Research Communications-
Appears in Collections:Liverpool Hospital

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing